General Catalyst Group Management LLC Makes New $3.88 Million Investment in Fractyl Health, Inc. $GUTS

General Catalyst Group Management LLC bought a new position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,884,186 shares of the company’s stock, valued at approximately $3,880,000. Fractyl Health makes up 2.1% of General Catalyst Group Management LLC’s holdings, making the stock its 7th largest position.

Other hedge funds have also modified their holdings of the company. Nantahala Capital Management LLC purchased a new stake in shares of Fractyl Health during the third quarter worth about $19,298,000. Bank of America Corp DE acquired a new stake in Fractyl Health during the second quarter worth approximately $4,791,000. Alyeska Investment Group L.P. purchased a new stake in Fractyl Health in the 3rd quarter worth approximately $8,981,000. Woodline Partners LP lifted its stake in shares of Fractyl Health by 821.1% during the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after purchasing an additional 4,908,693 shares during the period. Finally, Marshall Wace LLP boosted its holdings in shares of Fractyl Health by 234.9% during the fourth quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock worth $13,039,000 after purchasing an additional 4,156,969 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GUTS. Craig Hallum began coverage on shares of Fractyl Health in a research report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price objective for the company. Weiss Ratings raised shares of Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Thursday, June 4th. Finally, Wall Street Zen downgraded shares of Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.50.

Insiders Place Their Bets

In related news, Director William Bradley bought 68,493 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The stock was purchased at an average price of $0.73 per share, for a total transaction of $49,999.89. Following the transaction, the director directly owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This represents a 424.66% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ian Sheffield purchased 35,000 shares of the company’s stock in a transaction dated Wednesday, June 10th. The shares were acquired at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the purchase, the director owned 35,000 shares in the company, valued at $25,550. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 171,493 shares of company stock valued at $127,150 in the last quarter. 8.52% of the stock is currently owned by insiders.

Fractyl Health Stock Up 0.6%

Shares of NASDAQ:GUTS opened at $0.74 on Friday. The firm has a market cap of $118.08 million, a PE ratio of -0.84 and a beta of 2.32. The company has a fifty day simple moving average of $0.75 and a 200 day simple moving average of $0.66. The company has a current ratio of 3.15, a quick ratio of 3.15 and a debt-to-equity ratio of 1.41. Fractyl Health, Inc. has a 12-month low of $0.38 and a 12-month high of $2.44.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Monday, August 10th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. On average, equities research analysts anticipate that Fractyl Health, Inc. will post -0.53 EPS for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.